Literature DB >> 8968349

Neuroendocrine pharmacology of three serotonin releasers: 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butane (MBDB), 5-methoxy-6-methyl-2-aminoindan (MMAi) and p-methylthioamphetamine (MTA).

Q Li1, I Murakami, S Stall, A D Levy, M S Brownfield, D E Nichols, L D Van de Kar.   

Abstract

Serotonin (5-hydroxytryptamine, 5-HT)-releasing drugs are important experimental tools to examine the role of serotonergic nerve terminals in the secretion of hormones. The drugs 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butane (MBDB), 5-methoxy-6-methyl-2-aminoindan (MMAI) and p-methylthioamphetamine (MTA) have been suggested to be 5-HT releasers. The present study characterized MBDB, MMAI and MTA by using their effects on the secretion of the hormones adrenal corticotrophin (ACTH), corticosterone, prolactin, oxytocin and renin. The time course of the effect of MBDB, MMAI and MTA (5 mg/kg, i.p.) showed that the peak effect on plasma ACTH occurred 10 min after the injection, whereas the prolactin response did not reach a maximum until 30 min after injection. MBDB increased plasma renin concentration within 10 min, whereas the effect of MTA was significant only at 30 min after injection. All three 5-HT releasers decreased HR (within 5 min) and blood pressure (at 15 min after injection). MBDB, MMAI and MTA increased plasma ACTH, corticosterone, prolactin and renin levels in a dose-dependent manner, whereas no changes were observed in plasma vasopressin concentrations. MTA and MMAI, but not MBDB, significantly increased plasma oxytocin concentrations in a dose-dependent manner. Pretreatment of rats with fluoxetine blocked the ACTH response to MBDB and MMAI, but not to MTA. The prolactin response to all three 5-HT releasers was blocked by fluoxetine. The oxytocin response to MTA and MMAI was inhibited by fluoxetine. The renin responses to all three 5-HT releasers were not significantly inhibited by fluoxetine. The results suggest that MBDB, MMAI and MTA can increase the secretion of several hormones, at least in part, through stimulation of serotonergic neurotransmission. However, these three 5-HT releasers seem to have effects on other (and as yet uncharacterized) mechanisms that can stimulate the secretion of some hormones.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8968349

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  3 in total

1.  Para-methylthioamphetamine, a new amphetamine designer drug of abuse.

Authors:  D de Boer; T Egberts; R A Maes
Journal:  Pharm World Sci       Date:  1999-02

2.  Comparative metabolism of the designer drug 4-methylthioamphetamine by hepatocytes from man, monkey, dog, rabbit, rat and mouse.

Authors:  Helena Carmo; Jan G Hengstler; Douwe de Boer; Michael Ringel; Félix Carvalho; Eduarda Fernandes; Fernando Remião; Lesseps A dos Reys; Franz Oesch; Maria de Lourdes Bastos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-12-16       Impact factor: 3.000

3.  Pharmacological Characterization of 4-Methylthioamphetamine Derivatives.

Authors:  Fabrizzio G Guajardo; Victoria B Velásquez; Daniela Raby; Gabriel Núñez-Vivanco; Patricio Iturriaga-Vásquez; Rodrigo A España; Miguel Reyes-Parada; Ramón Sotomayor-Zárate
Journal:  Molecules       Date:  2020-11-13       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.